Apyx Medical (NASDAQ:APYX) Given New $6.00 Price Target at Craig Hallum

Apyx Medical (NASDAQ:APYX) had its price target lifted by stock analysts at Craig Hallum from $5.00 to $6.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Craig Hallum’s price target would indicate a potential upside of 58.52% from the company’s current price.

A number of other research firms have also recently issued reports on APYX. Roth Mkm initiated coverage on shares of Apyx Medical in a research note on Monday, December 15th. They issued a “buy” rating and a $6.00 price target on the stock. BTIG Research raised shares of Apyx Medical from a “neutral” rating to a “buy” rating and set a $6.00 price objective on the stock in a report on Wednesday. Wall Street Zen upgraded shares of Apyx Medical to a “hold” rating in a research report on Saturday, November 22nd. Zacks Research upgraded Apyx Medical to a “hold” rating in a research note on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Apyx Medical currently has an average rating of “Moderate Buy” and a consensus target price of $6.50.

Apyx Medical Price Performance

NASDAQ APYX traded up $0.34 during trading hours on Wednesday, reaching $3.79. The company’s stock had a trading volume of 256,466 shares, compared to its average volume of 125,104. The firm has a market capitalization of $144.74 million, a price-to-earnings ratio of -10.51 and a beta of 1.61. The company’s 50-day moving average is $3.74 and its two-hundred day moving average is $3.31. The company has a debt-to-equity ratio of 5.69, a current ratio of 4.44 and a quick ratio of 3.61. Apyx Medical has a 1-year low of $0.76 and a 1-year high of $4.50.

Apyx Medical (NASDAQ:APYX) last issued its quarterly earnings data on Tuesday, March 10th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.03. The company had revenue of $19.16 million for the quarter, compared to analyst estimates of $19.12 million. Apyx Medical had a negative return on equity of 151.01% and a negative net margin of 30.35%. On average, equities analysts predict that Apyx Medical will post -0.68 EPS for the current year.

Institutional Trading of Apyx Medical

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC purchased a new stake in shares of Apyx Medical in the 3rd quarter valued at approximately $28,000. Fisher Asset Management LLC purchased a new stake in Apyx Medical during the 2nd quarter worth about $34,000. Caprock Group LLC acquired a new stake in Apyx Medical in the third quarter valued at approximately $40,000. Hudson Bay Capital Management LP purchased a new position in Apyx Medical in the fourth quarter worth approximately $73,000. Finally, Osaic Holdings Inc. acquired a new position in Apyx Medical during the 2nd quarter worth approximately $50,000. 55.33% of the stock is currently owned by hedge funds and other institutional investors.

Key Apyx Medical News

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: BTIG upgraded Apyx from “neutral” to “buy” and set a $6.00 price target (~55% above the recent price), signaling institutional interest and providing upside narrative for the stock. Benzinga
• Positive Sentiment: Q4 2025 results beat estimates: EPS of ($0.03) vs. ($0.06) consensus and revenue $19.16M vs. $19.12M expected — a modest beat that reduces near-term execution risk. Press Release
• Positive Sentiment: Management issued FY2026 revenue guidance of $57.5M–$58.5M versus consensus ~$55.9M, implying ~9%–11% growth and backing the company’s guidance-driven narrative (the company also highlighted AYON body‑contouring commercialization). Press Release
• Positive Sentiment: Company outlined a 9%–11% revenue growth target for 2026 and emphasized the AYON launch as a growth catalyst — a clear product-driven growth story investors can model. Seeking Alpha
• Neutral Sentiment: Earnings call and coverage pieces (earnings highlights, breakdowns and call transcript) provide more detail on margins, commercialization cadence and cost structure; these are informative but largely reiterate the results and guidance. Earnings Call Highlights Benzinga Breakdown Conference Call Transcript
• Neutral Sentiment: Some short-interest data reported in various feeds contains inconsistent/erroneous zero values for March — this conflicting reporting creates short-term noise but not necessarily directional pressure. (Data discrepancies noted across sources.)
• Negative Sentiment: Earlier short-interest update (Feb. 27) showed a 22.3% increase to 173,573 shares shorted (≈0.5% of float) with ~2.7 days to cover — rising short interest is a potential headwind if negative sentiment persists.

About Apyx Medical

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.